FDA Approves Lipfendra Pill to Manage High LDL Cholesterol Levels

The US FDA has approved Lipfendra, a once-daily oral pill designed to manage high LDL cholesterol, offering a convenient alternative to traditional injectable PCSK9 inhibitors.

Clinical studies indicate the medication can reduce LDL cholesterol by nearly 60%, potentially lowering the long-term risk of heart attacks and strokes for patients with dyslipidaemia.

While the drug is currently approved in the US, experts note that its adoption in India depends on future pricing and competition to address the country's high cardiovascular disease burden.